<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200314046763N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-11</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of pre-capsular nerve  group block on opoid intra-operative consumption and analgesic effects after hip fracture surgery</public_title>
      <acronym>PENG</acronym>
      <scientific_title>The comparison of pericapsular nerve group block (PENG block) with fascia iliaca block on opioid intra-operative consumption and post-operative analgesic effects in extra-capsular and intra-capsular hip fracture</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/46612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Accidentalization was performed using block randomization method with 9 blocks and 2, 4, 6, 8 in blocks using blockrand package in R software, Blinding description: In the first step, the first and second intervention groups will be placed in the envelope. The study is double blind in that the patient will not be aware of the type of treatment, the evaluator will be different from the therapist, and the evaluator will be uninformed, but the therapist will be aware of the treatment. The evaluator will examine the patients at the beginning of their visit and refer them to a therapist if they have the conditions to study, and the therapist will select the treatment envelope according to the random block method. In the next step, the evaluator will perform the evaluation without knowing the assigned method.</study_design>
      <phase>3</phase>
      <hc_freetext>Pericapsular Nerve Group (PENG) block.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  PENG nerve block in intraoperative drug use and postoperative analgesic effects in intra-capsular and extracapsular hip fracture groups.After sterilizing the site and performing a skin anesthesia, the curve linear, low-frequency (2-5 MHz) is taken transversely on the Anterior Inferior iliac Spine, by rotating 45 degrees counterclockwise. The femoral artery and pectinus muscle are seen. The nidel is like the nidel of the control group and is inserted from the lateral to the medial in an in-plane so that its tip is located in the fascial muscle between the posterior psoas tendon and the posterior Ramus pubis after aspiration. Negative 0.5% vacuum solution is injected at 3 ml / kg with aspiration every 5 cc. Intervention 2: Control group: Patients with Fascia Iliaca Neural Block: Patients who undergo vital signs and appropriate intravenous lineage after receiving transfer to the operating room and monitoring with normal saline intake of 5-5 cc / kg, will undergo the following Fascia Iliaca nerve block as follows: Sterilize the block site and perform a skin anesthesia with a 2 cc Needle syringe with 1% lidocaine injection, with the help of a high-frequency linear transducer (10-25 MHz ultrasound device (S-Nerve Sonosite)) that is placed horizontally in the inguinal area. In-plan and with needle (B Brain (22 G, 80 mm, Stimuplex Ultra 360 in the amount of 3 ml / kg and a maximum of 40 ml of Rupivacaine 0.5% (Multeni) with direct view between the fascia The iliac and iliopsoas muscles are injected.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after unidentifiable people

When:
Start of access period 6 months after printing results

To whom:
Researchers working in academic and scientific institutions

Conditions:
1. Respecting the ethics and religion of the patients who participate in these studies.
 2-To help improve the validity of the data produced.
 3. Assist physicians in interpreting and minimizing disruption to clinical trials.
4. Prevent the recruitment of volunteers who are exposed to the dangers of high-risk trials.
 5. Mass media information on the effects of trials that do not conform to the interests of pharmaceutical companies.

Where to obtain:
drhamidrezasamadpour@gmail
00989125395847

How to obtain:
After logging into the system to provide results, three methods are envisaged in which the results can be accessed in different formats. Please click on "Search Output" to make the options visible in the menu.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamidreza Samadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 21, 12 Metri Taleghaani Ave., Nasim Ave., Kamaali Sharghi Blvd., Poonak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1476985487</zip>
        <telephone>+98 21 4460 4203</telephone>
        <email>hamidrezasamadpour@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamidreza Samadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 21, 12 Metri Taleghaani Ave., Nasim Ave., Kamaali Sharghi Blvd., Poonak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1476985487</zip>
        <telephone>+98 21 4460 4203</telephone>
        <email>hamidrezasamadpour@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with hip fractures
Elective surgery
Hemoglobin levels above 9 mg / dl
Age 50 to 75 years
ASA class I and II patients</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Other fractures or other lesions require surgery
History of drug or psychotropic addiction
Presence of psychiatric illnesses
Existence of coagulation disorder
Sensitivity to local anesthetics
Nervous disorders in the nerves of the lower extremities</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  PENG nerve block in intraoperative drug use and postoperative analgesic effects in intra-capsular and extracapsular hip fracture groups.After sterilizing the site and performing a skin anesthesia, the curve linear, low-frequency (2-5 MHz) is taken transversely on the Anterior Inferior iliac Spine, by rotating 45 degrees counterclockwise. The femoral artery and pectinus muscle are seen. The nidel is like the nidel of the control group and is inserted from the lateral to the medial in an in-plane so that its tip is located in the fascial muscle between the posterior psoas tendon and the posterior Ramus pubis after aspiration. Negative 0.5% vacuum solution is injected at 3 ml / kg with aspiration every 5 cc.</i_keyword>
      <i_keyword>Control group: Patients with Fascia Iliaca Neural Block: Patients who undergo vital signs and appropriate intravenous lineage after receiving transfer to the operating room and monitoring with normal saline intake of 5-5 cc / kg, will undergo the following Fascia Iliaca nerve block as follows: Sterilize the block site and perform a skin anesthesia with a 2 cc Needle syringe with 1% lidocaine injection, with the help of a high-frequency linear transducer (10-25 MHz ultrasound device (S-Nerve Sonosite)) that is placed horizontally in the inguinal area. In-plan and with needle (B Brain (22 G, 80 mm, Stimuplex Ultra 360 in the amount of 3 ml / kg and a maximum of 40 ml of Rupivacaine 0.5% (Multeni) with direct view between the fascia The iliac and iliopsoas muscles are injected.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 6, 12 and 24 hours after surgery. Method of measurement: Visual Analog Scale(VAS).</prim_outcome>
      <prim_outcome>Opioid intra-operative consumption. Timepoint: At the beginning of the surgery and then every 15 minutes. Method of measurement: Numeric rating scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-14</approval_date>
        <contact_name>Iran national committee for Ethics in biomedical research</contact_name>
        <contact_address>Tehran - Qods Township (West) - 13th Floor Between South Flamak and Zarafshan, Iran Sime St. - Headquarters of Ministry of Health and Medical Education, Block A Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
